Drugs / Emapalumab-Izsg
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05463133 | Jul 2022 → Dec 2032 expected | chronic granulomatous disease | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06694701 Comparator | Mar 2025 → Nov 2026 expected | infectious disease with sepsis | Hellenic Institute for the Study of Sepsis | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-03-18 | Sobi, Inc. | Results Results from EMBRACE Phase 2a study of emapalumab in interferon-gamma-driven sepsis presented at ISICEM sobi.com ↗ |
| 2026-01-07 | Sobi, Inc. | Results Sobi to advance Gamifant® (emapalumab) in interferon-gamma-driven sepsis (IDS) based on EMBRACE topline data sobi.com ↗
Sobi® (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant® (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with observed improvement in organ dysfunction and survival. |
All press releases naming this drug 3 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Emapalumab-Izsg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06694701 ↗ |
| Known as | emapalumab | “It aims to investigate if treatment with emapalumab, a monoclonal antibody which blocks IFNγ, may improve the outcome of patients with sepsis driven by the IDS (endotype of...” NCT06694701 ↗ |
| Action | Inhibit | “An interferon gamma blocking antibody used to prevent inflammation/engraftment syndrome post HSC transplant.” NCT05463133 ↗ |
| Modality | Monoclonal antibody | “emapalumab, a monoclonal antibody which blocks IFNγ” NCT06694701 ↗ |